Hypocalcaemia following denosumab in prostate cancer: A clinical review

Abstract

Objectives: Denosumab is often used in men with advanced prostate cancer to prevent skeletal-related events, but can be associated with severe hypocalcaemia. Our objective was to review the pathophysiology, identify risk factors and provide recommendations for prevention and management of denosumab-associated hypocalcaemia. Design: We reviewed the literature regarding denosumab-associated severe hypocalcaemia, defined as necessitating hospitalization for intravenous calcium treatment, in the context of prostate cancer. Patients: Men with prostate cancer with severe denosumab-associated hypocalcemia. Results: We identified 20 men with prostate cancer with severe denosumab-associated hypocalce..